Lusaris launches with $60 million
C&EN Global Enterprise November 7, 2022 Gina Vitale
Lusaris Therapeutics launched with $60 million in series A financing to develop serotonergic neuroplastogens for severe neuropsychiatric and neurological conditions. These compounds are said to induce favorable neural plasticity. Its lead candidate for treatment-resistant depression is a sublingual dissolvable tablet formulation of the psychedelic 5-MeO-DMT, using technology exclusively licensed from Catalent.